Narrative review / 2013
Weight loss is a key treatment for NAFLD, with ~5% loss improving steatosis and ~10% needed to improve steatohepatitis.
This review outlines nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), noting obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia as major risk factors. Weight loss is a cornerstone of therapy, where ~5% weight loss is believed to improve steatosis and ~10% is necessary to improve steatohepatitis. Pharmacologic agents like vitamin E and thiazolidinediones have also demonstrated promise in select patient subgroups.
- Study type
- Narrative review
- Who was studied
- Individuals with nonalcoholic fatty liver disease (NAFLD)
- What was measured
- Pathology, risk factors, diagnosis, and management of NAFLD and NASH
THE PAPER
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.
Masuoka HC, Chalasani N. Ann N Y Acad Sci, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.